NBIX

Neurocrine Biosciences, Inc. (NBIX) | Rumor.io

Neurocrine Biosciences

NBIX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,795

Bullish sentiment (50-day avg)98%

Price to earnings ratio20.2

Market capitalization14.3B

Earnings per share6.84

Dividend yield (TTM)—

Revenue (annual)2.9B

Net income (annual)478.6M

Social

What share of all stock conversation is about NBIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Aug 12

$NBIX slips 5.9% pre-market due to safety issues linked to Vykat XR, a drug for Prader-Willi syndrome, with reports of seven deaths and over 100 serious adverse events.
Neurocrine Biosciences' drug INGREZZA (valbenazine) has shown improved patient-reported quality of life and daily functioning for people living with tardive dyskinesia, according to publication of KINECT-PRO findings.
Experts flag safety risks for Vykat XR, citing deaths and severe side effects, while emphasizing that the reports do not establish a causal link to the drug, given the complex medical conditions and multiple health challenges common in the Prader-Willi population.

Generated by AI

Sentiment

Of the messages about NBIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +16.9	66.11% -12.72
Bearish	—	0% 0	0% -16.9	33.89% +12.72

Bullish· Apr 6

$NBIX's acquisition of $SLNO is expected to be immediately accretive to the company's top and bottom lines.
The deal is a 34% premium to $SLNO's current share price, providing significant upside potential for arbitrage players.
$NBIX's management team has a strong track record of execution, with successful launches and a growing market in the VMAT space.

Bearish· Mar 25

$NBIX's profit-taking phase has begun, with a significant drop in volume and large sell orders emerging.
The stock's inverted head and shoulders pattern has broken, leading to a sell-off, with many traders taking their profits and exiting the market.
$NBIX's price is being pushed lower by a combination of profit-taking and a lack of buying interest, with many traders expecting a further 5% drop in the stock's value.

Generated by AI

Topics

Of the messages about NBIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	52%	6.6%
Technical Analysis	—	—	0%	2.44%
Analysts	—	—	46%	0.76%
Earnings	—	—	2%	0.82%
Controversies	—	—	0%	0.01%
Macro	—	—	0%	89.37%

Earnings· Jul 31

Neurocrine Biosciences, Inc. ($NBIX) reported a loss of $0.07, beating consensus estimates of ($0.18).
$NBIX beat revenue estimates, reporting $96.91M in revenue.
$NBIX beat EPS loss estimates by $0.10 and revenue estimates by $12.27M.

Analysts· May 4

Neurocrine Biosciences ($NBIX) was upgraded to Buy from Neutral at Guggenheim with a $145 price target.
Analysts at Mizuho, Citigroup, and Barclays lowered their price targets for Neurocrine Biosciences to $111, $122, and $125 respectively.
Several analysts, including those at Guggenheim, Citigroup, Mizuho, and Barclays, maintained their Buy, Neutral, or Hold ratings for Neurocrine Biosciences while lowering their price targets.

Announcements· Apr 6

Neurocrine Biosciences (NBIX) has agreed to acquire Soleno Therapeutics (SLNO) for $53 per share in cash, valuing the deal at approximately $2.9 billion.
The acquisition adds Soleno's Prader-Willi syndrome therapy, Vykat XR, to Neurocrine's portfolio, which generated $190.4 million in revenue in 2025.
The deal is expected to close within 90 days and will be fully financed from existing cash reserves, with Neurocrine planning to optimize its capital structure by taking on a modest amount of pre-payable debt.

Technical Analysis· Jun 2

A potential bull flag on the daily chart formed, but the stock failed to break out on 6/2/15 and closed strong, suggesting a possible pullback to $4 before a run to $4.40-4.50.
The stock is expected to show support at $4 for a long position, with an entry point around $4.00 and a stop-loss at $3.90.
The author removed NBIX from consideration due to a broken pattern, and is now focusing on other stocks, including HLF, which has a potential bull flag with a key level at $52.50-$53.00.

Generated by AI

Community

Of the messages about NBIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	2.5%	12.5%	18.78%
Newcomers	100%	97.5%	87.5%	81.22%

Regulars· Apr 6

The acquisition of Soleno Therapeutics by Neurocrine Biosciences is a $2.9 billion deal, with Soleno's treatment for Prader-Willi disorder being a key focus.
The deal is expected to be accretive to Neurocrine's earnings, with the company's EPS projected to be over $7 next year.
The acquisition expands Neurocrine's endocrinology and rare disease portfolio, with the company acquiring Soleno for $53 per share.

Newcomers· Jun 11

Newcomers are discussing Neurocrine Biosciences' $2.9 billion deal related to its VYKAT XR treatment for Prader-Willi syndrome.

Generated by AI

News

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit

7d agoYahoo Finance

RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating

Neurocrine Biosciences (NBIX) has an average rating of buy and mean price target of $209.12, accordi

9d agofinance.yahoo.com

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

On August 12, Neurocrine Biosciences (NASDAQ:NBIX) published something unusual for a psychiatric drug: proof that patients feel the difference, not just that a clinician’s scale says they moved less. The KINECT-PRO findings showed INGREZZA easing the daily burden of tardive dyskinesia in ways a rating scale alone never captures. The timing matters, because the data […]

12d agoYahoo Finance

Also Discussed

Investors talking about NBIX also mention

#	Name	Attention
1	BioMarin Pharmaceutical IncBMRN	0%+0
2	Alnylam Pharmaceuticals, Inc.ALNY	0%0
3	Incyte Corp.INCY	0%new
4	Ionis Pharmaceuticals, Inc.IONS	0%new
5	ITCI - Intra-Cellular Therapies, Inc.	——
6	Acadia Pharmaceuticals Inc.ACAD	0%+0
7	RDUS - Radius Recycling, Inc.	——
8	Ultragenyx Pharmaceutical Inc.RARE	0.01%+0.01
9	SAGE - Sage Therapeutics, Inc.	——
10	SGEN - Seagen Inc.	——

Neurocrine Biosciences, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease chorea, as well as therapies for endocrine conditions including congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company also maintains a clinical-stage pipeline spanning additional neuroscience and endocrine targets, with research programs aimed at addressing underserved patient populations. Neurocrine Biosciences, Inc. plays an important role in specialty pharmaceuticals by combining marketed products with ongoing drug development across complex, chronic conditions that often require long-term management. Headquartered in San Diego, California, it serves patients and healthcare providers in the United States and internationally through its commercial operations and development activities.

Website

Location

6027 Edgewood Bend Court

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about NBIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Aug 12

$NBIX slips 5.9% pre-market due to safety issues linked to Vykat XR, a drug for Prader-Willi syndrome, with reports of seven deaths and over 100 serious adverse events.
Neurocrine Biosciences' drug INGREZZA (valbenazine) has shown improved patient-reported quality of life and daily functioning for people living with tardive dyskinesia, according to publication of KINECT-PRO findings.
Experts flag safety risks for Vykat XR, citing deaths and severe side effects, while emphasizing that the reports do not establish a causal link to the drug, given the complex medical conditions and multiple health challenges common in the Prader-Willi population.

Generated by AI

Sentiment

Of the messages about NBIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% +16.9	66.11% -12.72
Bearish	—	0% 0	0% -16.9	33.89% +12.72

Bullish· Apr 6

$NBIX's acquisition of $SLNO is expected to be immediately accretive to the company's top and bottom lines.
The deal is a 34% premium to $SLNO's current share price, providing significant upside potential for arbitrage players.
$NBIX's management team has a strong track record of execution, with successful launches and a growing market in the VMAT space.

Bearish· Mar 25

$NBIX's profit-taking phase has begun, with a significant drop in volume and large sell orders emerging.
The stock's inverted head and shoulders pattern has broken, leading to a sell-off, with many traders taking their profits and exiting the market.
$NBIX's price is being pushed lower by a combination of profit-taking and a lack of buying interest, with many traders expecting a further 5% drop in the stock's value.

Generated by AI

Topics

Of the messages about NBIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	52%	6.6%
Technical Analysis	—	—	0%	2.44%
Analysts	—	—	46%	0.76%
Earnings	—	—	2%	0.82%
Controversies	—	—	0%	0.01%
Macro	—	—	0%	89.37%

Earnings· Jul 31

Neurocrine Biosciences, Inc. ($NBIX) reported a loss of $0.07, beating consensus estimates of ($0.18).
$NBIX beat revenue estimates, reporting $96.91M in revenue.
$NBIX beat EPS loss estimates by $0.10 and revenue estimates by $12.27M.

Analysts· May 4

Neurocrine Biosciences ($NBIX) was upgraded to Buy from Neutral at Guggenheim with a $145 price target.
Analysts at Mizuho, Citigroup, and Barclays lowered their price targets for Neurocrine Biosciences to $111, $122, and $125 respectively.
Several analysts, including those at Guggenheim, Citigroup, Mizuho, and Barclays, maintained their Buy, Neutral, or Hold ratings for Neurocrine Biosciences while lowering their price targets.

Announcements· Apr 6

Neurocrine Biosciences (NBIX) has agreed to acquire Soleno Therapeutics (SLNO) for $53 per share in cash, valuing the deal at approximately $2.9 billion.
The acquisition adds Soleno's Prader-Willi syndrome therapy, Vykat XR, to Neurocrine's portfolio, which generated $190.4 million in revenue in 2025.
The deal is expected to close within 90 days and will be fully financed from existing cash reserves, with Neurocrine planning to optimize its capital structure by taking on a modest amount of pre-payable debt.

Technical Analysis· Jun 2

A potential bull flag on the daily chart formed, but the stock failed to break out on 6/2/15 and closed strong, suggesting a possible pullback to $4 before a run to $4.40-4.50.
The stock is expected to show support at $4 for a long position, with an entry point around $4.00 and a stop-loss at $3.90.
The author removed NBIX from consideration due to a broken pattern, and is now focusing on other stocks, including HLF, which has a potential bull flag with a key level at $52.50-$53.00.

Generated by AI

Community

Of the messages about NBIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	2.5%	12.5%	18.78%
Newcomers	100%	97.5%	87.5%	81.22%

Regulars· Apr 6

The acquisition of Soleno Therapeutics by Neurocrine Biosciences is a $2.9 billion deal, with Soleno's treatment for Prader-Willi disorder being a key focus.
The deal is expected to be accretive to Neurocrine's earnings, with the company's EPS projected to be over $7 next year.
The acquisition expands Neurocrine's endocrinology and rare disease portfolio, with the company acquiring Soleno for $53 per share.

Newcomers· Jun 11

Newcomers are discussing Neurocrine Biosciences' $2.9 billion deal related to its VYKAT XR treatment for Prader-Willi syndrome.

Generated by AI

Neurocrine Biosciences

Social

Aug 12

Bullish· Apr 6

Bearish· Mar 25

Earnings· Jul 31

Analysts· May 4

Announcements· Apr 6

Technical Analysis· Jun 2

Regulars· Apr 6

Newcomers· Jun 11

UBS cuts Neurocrine Biosciences stock price target to $214 on competition

Neurocrine Biosciences names Eiry Roberts as chief medical officer

Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit

RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

Also Discussed

Neurocrine Biosciences, Inc.

Company Information

Location

UBS cuts Neurocrine Biosciences stock price target to $214 on competition

Neurocrine Biosciences names Eiry Roberts as chief medical officer

Neurocrine Biosciences Names Eiry Roberts Chief Medical Officer

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit

RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

Also Discussed

Social

Aug 12

Bullish· Apr 6

Bearish· Mar 25

Earnings· Jul 31

Analysts· May 4

Announcements· Apr 6

Technical Analysis· Jun 2

Regulars· Apr 6

Newcomers· Jun 11